AC Immune (NASDAQ:ACIU) Trading Up 5% – Should You Buy?

AC Immune (NASDAQ:ACIU)’s stock price shot up 5% during trading on Monday . The stock traded as high as $3.20 and last traded at $3.18. 290,098 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 1,442,496 shares. The stock had previously closed at $3.03.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ACIU shares. Zacks Research raised shares of AC Immune from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 9th. BTIG Research restated a “buy” rating and set a $8.00 price objective on shares of AC Immune in a research note on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

AC Immune Stock Up 5.0%

The stock has a market cap of $319.30 million, a P/E ratio of -3.79 and a beta of 1.60. The business has a 50-day simple moving average of $3.09 and a 200-day simple moving average of $2.60.

AC Immune (NASDAQ:ACIU) last released its earnings results on Tuesday, November 4th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. AC Immune had a negative return on equity of 84.32% and a negative net margin of 1,642.89%.The business had revenue of $1.18 million for the quarter, compared to the consensus estimate of $0.81 million. On average, analysts predict that AC Immune will post -0.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ACIU. Private Advisor Group LLC acquired a new position in shares of AC Immune during the 3rd quarter worth about $48,000. Sei Investments Co. bought a new stake in AC Immune in the 2nd quarter valued at approximately $51,000. Susquehanna International Group LLP acquired a new position in AC Immune during the third quarter worth $63,000. Assenagon Asset Management S.A. bought a new position in shares of AC Immune in the 3rd quarter valued at about $549,000. Finally, Acadian Asset Management LLC increased its position in shares of AC Immune by 87.1% during the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after purchasing an additional 172,796 shares during the last quarter. Institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.